n/a
Abstract Title:

Recombinant Human Lactoferrin Augments Epirubicin Chemotherapy in Solid Ehrlich Carcinoma Bearing Mice.

Abstract Source:

Curr Drug Saf. 2022 Apr 29. Epub 2022 Apr 29. PMID: 35507797

Abstract Author(s):

Nahla E El-Ashmawy, Eman G Khedr, Amira Y El-Kady, Ghada M Al-Ashmawy

Article Affiliation:

Nahla E El-Ashmawy

Abstract:

BACKGROUND: Lactoferrin (LF) is a member of the transferrin family which is known for its immuno-modulatory properties. LF has been widely used as an anticancer medication in various cancers including breast cancer.

AIMS: The current study aimed to examine the molecular mechanisms underlying the therapeutic potential of recombinant human lactoferrin (rhLF), either alone or combined with epirubicin (EPI), in mice bearing solid Ehrlich carcinoma (SEC).

METHODS: SEC-bearing female mice (n=40) were divided into 4 equal groups. Mice were given rhLF orally (100 mg/kg/mouse) daily and/or EPI i.p (8 mg/kg/mouse). The experiment lasted for 14 days after which the samples were collected for measuring IL-18 and phosphorylated c-Jun N-terminal kinase (p-JNK) by ELISA and p53 gene expression by real time PCR.

RESULTS: Administration of rhLF, either alone or combined with EPI, markedly decreased the tumor volume and increased tumor inhibition rate as well as survival rate compared to either tumor control group or EPI-monotreated group. Also, co-administration of rhLF and EPI increased the level of activated JNKs and expression of p53 in tumor tissues compared to the tumor control group, exhibiting their pro-apoptotic properties. Moreover, the combined treatment with rhLF and EPI elevated IL-18 level in the intestinal mucosa compared to other experimental groups with a possible immune-enhancing effect.

CONCLUSION: Recombinant human lactoferrin exhibited potential anticancer and immuno-enhancing properties in mice with breast cancer. Co-treatment with rhLF and EPI proved to be a promising strategy in cancer treatment.

Study Type : Animal Study
Additional Links
Pharmacological Actions : Immunomodulatory : CK(4048) : AC(1475)

Print Options


Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.